- Home
- Publications
- Publication Search
- Publication Details
Title
Real-life experience with benralizumab during 6 months
Authors
Keywords
-
Journal
BMC Pulmonary Medicine
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-29
DOI
10.1186/s12890-020-01220-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dosis acumulada de corticoides sistémicos: una información relevante en medicina
- (2020) Pere Casan Clarà et al. ARCHIVOS DE BRONCONEUMOLOGIA
- Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways
- (2020) Didier Cataldo et al. JOURNAL OF ASTHMA
- Efficacy and safety of reslizumab in severe asthma patients with inadequate response to omalizumab: a multicentre, open-label, pilot study
- (2019) Luis A. Pérez de Llano et al. Journal of Allergy and Clinical Immunology-In Practice
- Estudio ATAUD: la necesidad de mejorar la adherencia
- (2019) Carlota Rodríguez-García et al. ARCHIVOS DE BRONCONEUMOLOGIA
- The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
- (2019) Kenneth R. Chapman et al. ALLERGY
- Aproximación «biológica» al tratamiento del asma
- (2019) Pere Casan Clarà et al. ARCHIVOS DE BRONCONEUMOLOGIA
- Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma
- (2019) I Dávila González et al. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY
- Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
- (2019) Luis Pérez de Llano et al. RESPIRATORY MEDICINE
- Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma
- (2019) Pasquale Comberiati et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose
- (2019) Corrado Pelaia et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma
- (2019) David J. Jackson et al. ADVANCES IN THERAPY
- Eosinophilic and Noneosinophilic Asthma
- (2018) Tara F. Carr et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
- (2018) Bradley E. Chipps et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Más Platón y menos Prozac ® : llega el ASMA-ZUMAB
- (2018) Pere Casan et al. ARCHIVOS DE BRONCONEUMOLOGIA
- “…I've said I wish I was dead, you'd be better off without me”: A systematic review of people's experiences of living with severe asthma
- (2018) Daniela Eassey et al. JOURNAL OF ASTHMA
- Outcomes of the Montana Asthma Home Visiting Program: A home-based asthma education program
- (2018) Jessie C. Fernandes et al. JOURNAL OF ASTHMA
- Más Platón y menos Prozac ® : llega el ASMA-ZUMAB
- (2018) Pere Casan et al. ARCHIVOS DE BRONCONEUMOLOGIA
- A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma
- (2018) Khalid Al Efraij et al. JOURNAL OF ASTHMA
- Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
- (2018) William W Busse et al. Lancet Respiratory Medicine
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
- (2016) A. Magnan et al. ALLERGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- The prevalence of severe refractory asthma
- (2015) Pieter-Paul W. Hekking et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
- (2015) Girolamo Pelaia et al. MEDIATORS OF INFLAMMATION
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- Targeting eosinophils in allergy, inflammation and beyond
- (2013) Patricia C. Fulkerson et al. NATURE REVIEWS DRUG DISCOVERY
- Factores asociados con el control del asma en pacientes de atención primaria en España: el estudio CHAS
- (2010) Francisco Javier González Barcala et al. ARCHIVOS DE BRONCONEUMOLOGIA
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
- (2009) Prescott G. Woodruff et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials
- (2009) Nick Freemantle et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started